Caricamento...

Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy

PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment. Kessel et al. [Theranostics 2019;9:4841-8] reported for the fi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Theranostics
Autori principali: von Eyben, Finn Edler, Kulkarni, Harshad R., Baum, Richard P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Ivyspring International Publisher 2020
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7163457/
https://ncbi.nlm.nih.gov/pubmed/32308757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.44568
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !